Since November 2014 nintedanib (trade name: Vargatef) has been approved in combination with docetaxel for the treatment of adults with advanced non-small cell lung cancer (NSCLC) of the glandular tissue (adenocarcinoma) who have already received chemotherapy. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether this new drug offers an added benefit over the appropriate comparator therapy.

According to the findings, there is an indication of a minor added benefit of nintedanib in combination with docetaxel in patients without brain metastases. However, in patients with brain metastases, the new drug has more disadvantages than chemotherapy with docetaxel alone. This results in a hint of a lesser benefit of nintedanib with the extent “considerable”.

For more details, go to: https://www.iqwig.de/en/press/press-releases/press-releases/nintedanib-in-lung-cancer-added-benefit-depends-on-disease-severity.6633.html